USANA Health Sciences, Inc. (NYSE:USNA) Insider Joshua Foukas Sells 5,732 Shares

USANA Health Sciences, Inc. (NYSE:USNA) insider Joshua Foukas sold 5,732 shares of USANA Health Sciences stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total transaction of $186,519.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

USANA Health Sciences Stock Performance

USANA Health Sciences stock opened at $30.38 on Friday. The firm has a market capitalization of $579.12 million, a price-to-earnings ratio of 10.74, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98. USANA Health Sciences, Inc. has a fifty-two week low of $27.71 and a fifty-two week high of $50.32. The stock’s fifty day moving average is $32.79 and its two-hundred day moving average is $36.05.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. The company had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. As a group, sell-side analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

USNA has been the topic of several analyst reports. DA Davidson reduced their price target on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. Finally, StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. R Squared Ltd acquired a new position in USANA Health Sciences during the 4th quarter valued at approximately $28,000. Safe Harbor Fiduciary LLC acquired a new stake in shares of USANA Health Sciences during the third quarter worth $30,000. KBC Group NV raised its position in shares of USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after purchasing an additional 519 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of USANA Health Sciences during the fourth quarter worth $83,000. Finally, Quantbot Technologies LP purchased a new position in shares of USANA Health Sciences during the fourth quarter valued at $132,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.